Abpro (NASDAQ:ABP – Get Free Report) and Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitability.
Profitability
This table compares Abpro and Cartesian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Abpro | N/A | N/A | -344.76% |
| Cartesian Therapeutics | N/A | N/A | -11.95% |
Earnings & Valuation
This table compares Abpro and Cartesian Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abpro | $180,000.00 | 22.67 | -$7.23 million | ($4.23) | -0.35 |
| Cartesian Therapeutics | $38.91 million | 4.20 | -$77.42 million | ($1.56) | -4.03 |
Abpro has higher earnings, but lower revenue than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings for Abpro and Cartesian Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abpro | 1 | 1 | 0 | 0 | 1.50 |
| Cartesian Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
Abpro presently has a consensus target price of $120.00, suggesting a potential upside of 7,900.00%. Cartesian Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 513.06%. Given Abpro’s higher probable upside, analysts clearly believe Abpro is more favorable than Cartesian Therapeutics.
Institutional and Insider Ownership
23.3% of Abpro shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 13.7% of Abpro shares are owned by insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Cartesian Therapeutics beats Abpro on 7 of the 11 factors compared between the two stocks.
About Abpro
Abpro Holdings Inc. is a biotechnology company. The company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Abpro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abpro and related companies with MarketBeat.com's FREE daily email newsletter.
